CNTA: Centessa Pharmaceuticals Company Short-Term Debt

Symbol and logo of brand centessa.com (CNTA)

Centessa Pharmaceuticals (CNTA) employs a portfolio approach to managing biotech startups, developing drugs for hematological and rare pathologies. The short-term debt volume on the GURU.Markets daily service chart reflects the current status of 0.01. The company is fighting for leadership in orphan disease therapy against industry behemoths, yet dependence on trial outcomes and the risk of side effects render future profits hypothetical.

CNTA (Centessa Pharmaceuticals plc) Company Short-Term Debts history from 07/04/2022 to 07/04/2026

Financial and market metric breakdowns for Centessa Corp (CNTA)

- current quotes and average value forecast:
Price Chart Centessa|CNTA - Fair Value Consensus
- market capitalization information:
Market Value Centessa|CNTA - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Centessa Pharmaceuticals|CNTA - Book Capitalization|Market Cap to Net Assets Ratio centessa.com|CNTA - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Centessa Pharmaceuticals|CNTA - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Centessa Pharmaceuticals|CNTA - Company Cumulative Debt|Debt to Book Value Centessa|CNTA - Company Long-Term Debts|Company Short-Term Debt Centessa Pharmaceuticals|Quick Liquidity centessa.com
- net income and valuation multiples indicators:
CNTA - Company Net Income
Basic company analysis:Centessa - CNTA
Mass-produced product of Centessa Corp

Assessing the reliability of equity assets begins with an analysis of liquidity and the issuer's ability to service current obligations. The total volume of borrowings maturing within one year determines the financial stability of Centessa Pharmaceuticals (CNTA), which is critical during prolonged sleep drug trials, as short-term debt load reflects the availability of capital to sustain the innovation cycle until the point of commercialization.

Competitors of Centessa Pharmaceuticals (CNTA)

JAZZ - Company Short-Term Debt|Company Short-Term Loans and Borrowings CYTK (Cytokinetics Inc.)|PTC Therapeutics Corp (PTCT) - Company Short-Term Debt|Company Current Liabilities Scholar Rock Inc.|DYN (Dyne Therapeutics, Inc.) - Company Short-Term Debts|Company Short-Term Debts edgewisetx.com|Company Current Liabilities RAPP (Rapport Therapeutics)|ALMS (Alumis Inc) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Kempharm ZVRA|CTNM: Company Short-Term Indebtedness|Larimar Therapeutics - Company Short-Term Debts|Short-Term Debt Capricor Therapeutics|TRDA (Entrada Therapeutics, Inc.) - Company Current Liabilities|Channel Therapeutics Inc. (PTHS) - Company Short-Term Debts|Company Short-Term Debt MediciNova Inc.|SER: Company Short-Term Loans and Borrowings|Company Short-Term Debt BioXcel Therapeutics (BTAI)|PMN - Short-Term Debt|Company Short-Term Debt Apimeds Pharmaceuticals US APUS|AEON Biopharma Inc. - Company Short-Term Debt|NLSP - Company Short-Term Debt|Short-Term Debt Bionomics Limited|HUGE: Company Short-Term Debts|Short-Term Indebtedness reatapharma.com RETA